Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:analyzes |
filed
|
| gptkbp:chemicalFormula |
C20H25N3O3S
|
| gptkbp:clinicalTrials |
pending
Phase 2 favorable multiple sites Wiley_Medical |
| gptkbp:collaborations |
international research teams
various research institutions |
| gptkbp:communityEngagement |
ongoing
|
| gptkbp:compatibleWith |
high
|
| gptkbp:contraindication |
allergic reactions
liver function abnormalities |
| gptkbp:currentStatus |
completed
|
| gptkbp:developedBy |
Wiley_Medical
|
| gptkbp:dosageForm |
once daily
|
| gptkbp:drugInterdiction |
minimal
|
| gptkbp:endOfLife |
12 hours
|
| gptkbp:evaluates |
promising results
|
| gptkbp:firstClaim |
treatment of HIV/AIDS
|
| gptkbp:formulation |
tablet
|
| gptkbp:funding |
government grants
private investors |
| gptkbp:future_plans |
clinical trials
|
| gptkbp:hasPopulation |
HIV positive individuals
|
| gptkbp:healthcare |
provided
high adherence expected |
| gptkbp:historicalResearch |
long-term effects studies
exploring combination therapies resistance patterns studies |
| https://www.w3.org/2000/01/rdf-schema#label |
WME-720
|
| gptkbp:impact |
12 weeks
|
| gptkbp:is_monitored_by |
regular blood tests
|
| gptkbp:isResponsibleFor |
ongoing
|
| gptkbp:market |
not available
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:patentStatus |
patented
|
| gptkbp:regulatoryBody |
gptkb:FDA
EMA |
| gptkbp:regulatoryCompliance |
not yet approved
|
| gptkbp:releaseYear |
2020
|
| gptkbp:researchAreas |
ongoing
|
| gptkbp:researchFocus |
HIV resistance
|
| gptkbp:researchInterest |
academic institutions
peer-reviewed journals improve treatment outcomes obtained potential to change HIV treatment paradigm |
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
ongoing
under evaluation |
| gptkbp:sideEffect |
fatigue
headache nausea |
| gptkbp:targets |
HIV
children adults |
| gptkbp:triggerType |
inhibits viral replication
|
| gptkbp:type |
antiviral
|
| gptkbp:waterManagement |
urine
|